LON:ETX e-therapeutics (ETX) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About e-therapeutics Stock (LON:ETX) 30 days 90 days 365 days Advanced Chart Get e-therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range 9▼ 952-Week Range N/AVolume2.52 million shsAverage Volume758,869 shsMarket Capitalization£52.59 millionP/E RatioN/ADividend Yield3.35%Price TargetN/AConsensus RatingN/A Company Overview e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom. Read More Receive ETX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for e-therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ETX Stock News Headlinese-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 ...July 11, 2025 | morningstar.comMe-therapeutics plc: e-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 with Positive Non-clinical DataJuly 10, 2025 | finanznachrichten.deJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% of his time focused on AI… but Nova is only part of the story. Behind the scenes, Amazon has been quietly investing in a breakthrough called “Helios” tech—a core enabler of the $40 trillion AI revolution. While Nova grabs headlines, this technology could be what truly transforms Amazon’s future. But one tiny startup—not Amazon—may offer the bigger upside.August 2 at 2:00 AM | Stansberry Research (Ad)e-therapeutics plc: e-therapeutics Presents New Data Supporting ETX-312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASHMay 7, 2025 | finanznachrichten.dee-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASHMay 7, 2025 | finance.yahoo.comEnsem Therapeutics Announces U.S. FDA IND Clearance to Initiate Clinical Development of ETX-636April 22, 2025 | tmcnet.comElicio Therapeutics stock slides on $10M securities offeringJanuary 30, 2025 | msn.comEnsem Therapeutics Announces Presentation at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | businesswire.comSee More Headlines ETX Stock Analysis - Frequently Asked Questions How were e-therapeutics' earnings last quarter? e-therapeutics plc (LON:ETX) issued its quarterly earnings data on Tuesday, March, 17th. The company reported ($0.87) earnings per share for the quarter, topping analysts' consensus estimates of ($0.90) by $0.03. How do I buy shares of e-therapeutics? Shares of ETX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of e-therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that e-therapeutics investors own include 4D pharma (DDDD), Omega Diagnostics Group (ODX), B&M European Value Retail (BME), Coats Group (COA), Eurasia Mining (EUA), genedrive (GDR) and Greencore Group (GNC). Company Calendar Last Earnings3/17/2020Today8/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ETX CIKN/A Webwww.etherapeutics.co.uk Phone+44-1993-880000FaxN/AEmployees35Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£10.06 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.75% Return on Assets-29.10% Debt Debt-to-Equity Ratio0.33 Current Ratio22.20 Quick Ratio20.13 Sales & Book Value Annual Sales£295 thousand Price / Sales0.00 Cash FlowN/A Price / Cash Flow5.07 Book ValueGBX 5 per share Price / BookN/AMiscellaneous Outstanding Shares584,330,000Free FloatN/AMarket Cap£52.59 million OptionableNot Optionable Beta0.46 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (LON:ETX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredMicrosoft's Next Big Bet?Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-fre...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding e-therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share e-therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.